20 May 2013: STENTYS Enrolls First Heart Attack Patient in Pivotal U.S. Clinical Trial
09 March 2013: STENTYS Self-Apposing® Stent Demonstrates Lowest Mortality Rate Among Large Heart Attack Trials
26 February 2013: STENTYS to Present Final Results From 1,000 Heart Attack Patient Study at ACC.13
03 January 2013: STENTYS clinical study demonstrating superiority of its stents published in American College of Cardiology journal
22 October 2012: FDA Approval to Initiate First U.S. Clinical Trial With Self-Apposing® Stent
22 October 2012: Interim results on 1 year of APPOSITION III trial
15 October 2012: Presentation of the One-Year Interim Results From APPOSITION III Study at TCT Conference
26 September 2012: Launch of a New Stent-Delivery System
14 June 2012: STENTYS starts clinical trial to broaden portfolio with new drug-eluting stent
16 May 2012: APPOSITION III Results
14 May 2012: STENTYS expands its product offerings
26 March 2012: STENTYS Self-Apposing technology supported by breaking new scientific evidence
08 February 2012: Increased reimbursement of Self-Expanding drug-eluting stents in Germany now for all indications
01 February 2012: STENTYS concludes clinical trial ahead of plan
08 November 2011: Outstanding interim results of STENTYS international clinical study APPOSITION III
12 October 2011: STENTYS Self-Apposing Stents in “perfect apposition to vessels” after treating patients with heart attacks
21 September 2011: STENTYS completes enrollment of APPOSITION III study
15 September 2011: Over 1000 patients have benefited from STENTYS Self-Apposing technology
31 August 2011: 2011 Half-Year results
26 July 2011: Revenues for the 1st half of 2011
20 June 2011: Prof. Gilles Montalescot joins STENTYS Scientific Advisory Board
08 June 2011: STENTYS recruits Country managers for France and Italy
18 May 2011: STENTYS joins Stent for Life Initiative
16 May 2011: Stenting in STEMI: Does Size Matter?
02 May 2011: STENTYS enrolls first 250 patients within the framework of its Apposition III international study
17 March 2011: STENTYS expands operations into four additional European countries
23 February 2011: Increased reimbursement of STENTYS drug-eluting stent in Germany
09 December 2010: STENTYS begins large-scale, “real life” study with its selfapposing stent for treatment of Heart Attacks
50 patients already enrolled
23 November 2010: STENTYS appoints Mr Michel Darnaud to its Board of Directors
22 September 2010: APPOSITION II clinical trial results
STENTYS self-apposing stent proves superior to conventional treatment of Acute Myocardial Infarction
09 September 2010: STENTYS completes enrollment in clinical study of its breakthrough stent to treat Acute Myocardial Infarction.
02 September 2010: STENTYS appoints Stanislas Piot as Chief Financial Officer
05 May 2010: STENTYS drug-eluting self-expanding stent receives CE Marking.
01 March 2010: STENTYS self-expanding stent receives CE Marking to treat acute coronary syndrome (ACS).
06 February 2010: STENTYS drug-eluting self-expanding coronary stent shows 4% restenosis in complex lesions.
01 December 2009: First patient enrolled in randomized study of STENTYS self-expanding stent vs. conventional stent to treat acute myocardial infarction (AMI).
31 October 2009: STENTYS expands Scientific Advisory Board (SAB) on heels of reporting successful clinical trial results for world’s first self-expanding stent to treat AMI.
15 September 2009: STENTYS discloses results for world’s first clinical study to treat acute myocardial infarction (AMI) with a self-expanding stent.
